Prostate Cancer Patients May Benefit from New Fusion Biopsy Systems by UC-Care

Prostate Cancer Patients May Benefit from New Fusion Biopsy Systems by UC-Care
UC-Care and Axella BioVentures announced the introduction of the Navigo and SmartBx Systems, which they believe to offer the most advanced and accurate means of performing a prostate biopsy currently available, into medical practice in the United States. Navigo is a device that helps physicians to plan, place, image, and record prostate biospy samples in high-resolution 3-D. It fuses MRI images that have been previously captured with live transrectal ultrasound (TRUS) when the ultrasound transducer is inserted in the tumor site during the biopsy. Westmed Medical Group, a large multi-specialty group based in New York, was the first to acquire the Navigo system. "It is a refinement and extension of already accepted and standard MRI fusion diagnostic techniques," Dr. Steven Meixler, co-medical director at Westmed, said in a press release. Navigo is "the most advanced MRI fusion device and better suited for today's prostate cancer environment than any alternative MRI fusion device," added Dr. Judd Boczko, an urologist at Westmed. The system can also aid in follow-up biopsies in prostate cancer patients under active surveillance, by fusing past and present biopsy techniques. It also works in the absence of an MRI, allowing the 3-D modeling of the prostate and ac
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *